EFFECT OF CD8+ T CELL ACTIVATION ON LIVE ATTENUATED HEPATITIS A VACCINE IN OBESITY/OVERWEIGHT CHILDREN AND YOUNG ADULTS

Effect of CD8+ T Cell Activation On Live Attenuated Hepatitis A vaccine in Obesity or Overweight Children

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210825005

Enrollment

200

Registered

2021-08-25

Start date

2021-08-25

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity Overweight Normal weight Children Lived attenuated hepatitis A vaccine CD8 T cell IFN gamma Obesity

Interventions

The normal weight group will receive the lived attenuated hepatitis A vaccine 0.5 ml SC (same vaccine and dose as the obesity group) Then we will collect the blood after vaccination around 8 week,The

Active Comparator Biological/Vaccine,Active Comparator Biological/Vaccine

Normal weight group,Obesity group

Eligibility

Sex/Gender

All

Age

6 Years to 35 Years

Inclusion criteria

Inclusion criteria: Children/adolescent aged 6-25 years old who visit at King Chulalongkorn Memorial Hospital (OPD, annual medical check-up, IPD), and volunteer students who has met WHO obesity criteria

Exclusion criteria

Exclusion criteria: - Children/young child/adolescent who received Hepatitis A vaccine - Children/young child/adolescent who has an immunodeficiency or taking any immunosuppressive medication

Design outcomes

Primary

Measure	Time frame
IFN gamma-CD3 T cell-CD8 T cell 8 weeks ELISPOT	—

Secondary

Measure	Time frame
Granzyme B 8 weeks Flow cytomtrey	—

Countries

Thailand

Contacts

Public ContactTanatchabhorn Soponkanabhorn

Department of Pediatric, Faculty of Medicine, Chulalongkorn University

philopink@gmail.com0878086320

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026